CapitalStars Financial Research Pvt Ltd


CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market.we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors.we provide intraday as well as delivery stock tips in NSE and BSEand commodity tips in MCX and NCDEX. Read More

Commodity Market Services

Commodity Market Services

In this service we provide 3-4 intraday calls in MCX with a high level of accuracy. The calls are given in Precious Metals, Base Metals and Energies. You can also avail Free Tips for two days to test our accuracy and if satisfied you can join the services with Capital Stars. Read More

Nifty Market Services

Nifty Future Services

We provide you around 1-2 nifty calls, Bank Nifty Futures, nifty futures tips, sgx nifty tips Daily. You can gain more profit, Get 2 days free trial calls. Read More

Equity Market Services

Equity Market Services

In this service we provide 2-4 intraday stock cash calls in NSE/BSE with a high level of accuracy.You can also avail Free Stock Tips for two days to test our accuracy and if satisfied you can join stock cash services with Capital Stars. Read More

Register now

CapitalStars provides Free Trial in Intraday as well as in Positional Services of Equity, Derivatives, and Commodities and Forex Markets. We provide recommendations in NSE, BSE, MCX, NCDEX, and MCX-SX etc. We render you enough entry and exit time in our calls so clients can easily maximize their profits. Read More

Friday, 12 May 2017

Dr Reddy's hits 52-week low ahead of Q4 results : 12 May 2017

Dr. Reddy

Dr Reddy’s Laboratories hit 52-week low of Rs 2,554 on BSE in intra-day trade ahead of its January-March quarter (Q4FY17) results today.

Since February 3, post October-December (Q3FY17) results, the stock of drug Company has underperformed the market by falling 19% as compared to 7% rise in the S&P BSE Sensex.

Dr Reddy's had reported 19% year on year (YoY) drop in net profit at Rs 470 crore in Q3FY17 against Rs 579 crore during the corresponding quarter in FY16. Revenues for Q3FY17 dropped 7% to Rs 3,707 crore as against Rs 3,968 crore in Q3FY16.

Edelweiss Securities expects Dr Reddy’s US revenue (USD 236 million) to decline 16% YoY in Q4FY17, due to increased competition in Dacogen, Valcyte and Vidaza and also down 4% QoQ due to lack of launches.

“Russia/CIS revenues are likely to up 10% YoY in CC and currency up around 26% YoY. Expect growth in India to be mellow at 12% YoY. Gross margin to come back to around 56% level after Q3FY17's abnormal margin that was driven by seasonality of injectables,” the brokerage firm said in Q4 results preview.

“Dr Reddy’s is likely is likely to deliver a weak set of numbers due to base effect, capacity constraint, litigation issues and increased 
competition in the US”, ICICI Securities said in Q4 results preview.

Dr Reddy’s said on April 28, that the US Food and Drug Administration (USFDA) issued a Form-483 with 11 observations after inspecting its manufacturing unit-3 at Bachupally in Hyderabad.

Earlier, on March 8, the company said the USFDA issued a Form 483 with 13 observations for the company’s formulation manufacturing facility at Duwada, Visakhapatnam.

At 10:44 am; the stock was down 1% at Rs 2,563 on BSE as compared to 0.17% decline in the benchmark Senex. A combined 200,441 shares changed hands on the counter on BSE and NSE so far.

Capitalstars Financial Research Private Limited is a research house and an investment advisory carrying out operations in the Indian Equities and Commodity market.We also provide 2 days free trial to our client.Join our services and trade with us. 

Get more details here:-

* Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647


Post a Comment